Targeted synthetic drugs

POS0549 OUTCOMES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH INTRAVENOUS OR SUBCUTANEOUS BELIMUMAB: A POST-HOC EFFICACY META-ANALYSIS BY BICLA CRITERIA
I. Parodis, J. Lindblom, N. Çetrez, L. Palazzo, S. Oon, H. Ala, R. F. Van Vollenhoven, E. Morand, A. Levitsky, M. Nikpour

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1010-1011; DOI: 10.1136/annrheumdis-2024-eular.5743
POS0819 ANTI-CD19 CAR T CELL THERAPY IN SYSTEMIC SCLEROSIS – EXPERIENCES FROM TUEBINGEN IN 3 PATIENTS
J. Henes, A. C. Pecher, L. Hensen, R. Klein, A. Stanger, C. Faul, W. Bethge, C. Lengerke

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1038; DOI: 10.1136/annrheumdis-2024-eular.1746
POS0798 EFFICACY, SAFETY AND RADIOGRAPHIC OUTCOMES FROM THE PHASE 3 SELECT-AXIS 2 STUDY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND AN INADEQUATE RESPONSE TO BIOLOGIC DMARD THERAPY: 2-YEAR DATA
X. Baraliakos, D. Van der Heijde, J. Sieper, R. Inman, H. Kameda, W. P. Maksymowych, A. Shmagel, I. Lagunes, X. Bu, P. K. Wung, A. Deodhar

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 914-915; DOI: 10.1136/annrheumdis-2024-eular.2314
POS0813 PREDICTORS OF RESPONSE TO bDMARDs AND tsDMARDs THERAPY: THE ROLE OF MUSCULOSKELETAL ULTRASOUND AND POTENTIAL NEW BIOMARKERS
G. Cozzi, M. Lorenzin, F. Oliviero, L. Scagnellato, A. Damasco, C. Cosma, A. Doria, D. Basso, R. Ramonda

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 932-933; DOI: 10.1136/annrheumdis-2024-eular.4534
POS0809 SWITCH OR SWAP? SECOND TARGETED THERAPY CHOICE IN PATIENTS WITH SPONDYLOARTHRITIS: A COHORT STUDY WITHIN THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)
C. Miceli Richard, R. Curmin, B. Flachaire, S. Pinto, F. Tubach, T. Pham

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 934; DOI: 10.1136/annrheumdis-2024-eular.4966
POS0536 SAFETY, PHARMACOKINETICS, BIOMARKER, AND EFFICACY OF E6742, A DUAL ANTAGONIST OF TOLL-LIKE RECEPTOR 7 AND 8, IN A FIRST-IN-PATIENT PHASE1/2 STUDY IN SYSTEMIC LUPUS ERYTHEMATOSUS
Y. Tanaka, A. Kumanogoh, T. Atsumi, T. Ishii, F. Tago, M. Aoki, K. Watanabe, S. Yamamuro, S. Akira

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 949; DOI: 10.1136/annrheumdis-2024-eular.1019
POS0674 DOES JAK SELECTIVITY MAKE A DIFFERENCE? A COMPARISON BETWEEN THE RETENTION RATE OF THREE JAK INHIBITORS: A RETROSPECTIVE REAL-WORLD EVIDENCE MULTICENTER STUDY FROM THE JAK-GULF REGISTRY
A. S. Zayat, O. Alsaed, M. A. Omair, A. Hussein, S. Allam, A. Poil, M. Ahmed, K. Ghassan Bohuliga, A. M. Alragheb, E. N. Etrug, N. Kalantan, R. Namas, S. Attar, W. Hafiz, S. Alemadi, S. Hannawi

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 831; DOI: 10.1136/annrheumdis-2024-eular.4671
POS0676 GENETIC BIOMARKERS FOR TOFACITINIB TREATMENT RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS.
S. Janahiraman, C. L. Too, S. S. Ch’ng, L. H. Eow, E. Mageswaren, A. L. Lim, H. C. Chong, P. S. Ong, A. Mohamed Ismail, S. M. Abd Rahim, C. R. Ng, D. M. Suahilai, A. H. Ramlan, N. S. Shahril, C. O. Leong

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 833; DOI: 10.1136/annrheumdis-2024-eular.4792
POS0681 ARE JAKi PLASMA LEVELS RELATED TO CLINICAL RESPONSE IN RHEUMATOID ARTHRITIS?: THE MEASURE STUDY, A MULTICENTRE PROSPECTIVE COHORT STUDY
B. Frade-Sosa, C. A. Chacur, J. Inciarte-Mundo, C. Valero, M. Novella-Navarro, H. Borrell Paños, Á. Prior-Español, E. Graell, P. Zubiaur, G. Villapalos, N. Sapena, L. Tobalina, A. Gómez-Centeno, L. Mateo, A. Balsa, S. Marsal Barril, R. Garcia-Vicuña, R. Sanmarti

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 841; DOI: 10.1136/annrheumdis-2024-eular.5110
POS0478 SURVIVALTO b/tsDMARDs IN PATIENTS AFTER FULFILLING DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS CLASSIFICATION
M. Novella-Navarro, V. Ruiz, N. López-Juanes, C. A. Chacur, I. Monjo-Henry, L. Nuño, M. G. Kafati Sarmiento, D. Peiteado, A. Villalba, E. Fernández-Fernández, M. Sanz-Jardón, R. Sanmarti, C. Plasencia-Rodríguez, A. Balsa

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 847-848; DOI: 10.1136/annrheumdis-2024-eular.5546

Main menu

Targeted synthetic drugs

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Targeted synthetic drugs

Pages